Cell And Gene Therapy Videos

31. Harnessing Potential: Innovations And Improvements In Viral Gene Therapy 4/28/2025

    Review the potential of AAV-mediated gene therapy as a platform approach to treat multiple genetic neurological diseases, and explore suggestions to streamline translational studies and reduce costs.

32. FUJIFILM Diosynth Biotechnologies Capacity Update April 2025: Cell & Gene Therapy 4/24/2025

    Director of Commercial Development, Serat Ali, describes FDBs' Advanced Therapy capabilities, discusses their global facilities network, and provides a capacity update.

33. Vinta Bio Capacity Update April 2025: Cell & Gene Therapy 4/24/2025

    Uncover how an intensified adherent AAV manufacturing process is unlocking high-yield, low-impurity clinical production with over 95% full capsids in a streamlined, compact platform.

34. Kincell Bio Capacity Update April 2025: Cell & Gene Therapy 4/24/2025

    Explore how expert CMC strategies and clinical manufacturing experience can lay the groundwork for the successful commercialization of advanced cell therapies.

35. Capacity Update April 2025: Cell & Gene Therapy 4/24/2025

    Witness how NYBCe and CCS are transforming cell and gene therapy development with end-to-end CDMO solutions, advanced logistics, and a growing innovation hub in Louisville.

36. Miltenyi Biotec B.V. & Co. KG Capacity Update April 2025: Cell & Gene Therapy 4/24/2025

    In this presentation, Shaan Gareeb highlights the capabilities of our Cell Therapy Center of Excellence in San Jose, California, one of five global Miltenyi Bioindustry sites.

37. Optimization-By-Design: A Critical Factor In Viral Vector Scale Up, Scale Down 4/24/2025

    Focusing on critical parameters such as cell culture conditions, viral vector yield, and downstream purification strategies, can drive the success of scale-up and scale-down models for AAV production.

38. SK pharmteco Capacity Update April 2025: Cell & Gene Therapy 4/24/2025

    Our integrated expertise — from plasmid science to viral vector and cell therapy manufacturing — can accelerate and de-risk the development of your advanced therapies.

39. Advancing Cell & Gene Therapies To Patients 4/24/2025

    Discover how we apply our expertise and know-how to efficiently advance your viral vector-based therapeutic through any phase, while enhancing quality and de-risking production.

40. SK pharmteco Capacity Update April 2025: Analytical Services 4/22/2025

    Get the quality, compliance, and accelerated development support you need for your small molecule and cell and gene therapy program with our advanced analytical testing services.